Duke University

Beth Israel Deaconess Medical Center, Inc.

The Uab Research Foundation (the University of Alabama at Birmingham)

Los Alamos National Security, LLC

University of Pennsylvania

University of California

Leland Stanford Junior University

The United States of America, as Represented by the Secretary, Department of Health and Human Services

University System of Maryland

Boston University

The University of North Carolina at Chapel Hill

Dana-Farber-Cancer Institute Inc.

Children's Medical Center Corporation

Sloan-Kettering Institute for Cancer Research

Albert Einstein College of Medicine

Hua-Xin Liao

Barton F Haynes

Bette T Korber

Beatrice H Hahn

Norman L Letvin

M Anthony Moody

George M Shaw

Feng Gao

William M Fischer

Edward F Patz, Jr

Elizabeth Gottlin

Michael J Campa

Mattia Bonsignori

S Munir Alam

Dhavalkumar D Patel

Ying Ying Li

Peter T Hraber

Thomas B Kepler

Julie Decker

Peter D Kwong

John R Mascola

Tongqing Zhou

Kevin J Wiehe

Kevin O Saunders

Scott D Boyd

Samuel J Danishefsky

William R Jacobs, Jr

Joseph G Sodroski

Peter U Park

Munir Alam

Rebecca M Lynch

Denise Kothe

LaTonya Williams

Gilad Adi Ofek

Stephen C Harrison

John Mascola

Georgia D Tomaras

Ronald I Swanstrom

Gregory D Sempowski

Peter Kinam Park

Robert M De Lorimier

David C Montefiori

Michael Anthony Moody

Norman Letvin

Li-Hua Ping

Ryan Meyerhoff

Todd Bradley

Baptiste Aussedat

Yusuf Vohra

Anthony M Moody

Sallie Permar

James Whittle

Mark Cayabyab

Jae-Sung Yu

Avi-Hai Hovav

Denise L Monti

Aaron G Schmidt

Karen L Patton

Samuel Danishefsky

Peter Kwong

Scott Boyd

Jr Edward F Patz

Peter Park

Nelson Michael

Jerome Kim

Susan B Zolla-Pazner

Munir S Alam

Disclosed herein are Complement factor H (CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors.

Inhibitors of complement factor H

The invention is directed to HIV-1 neutralizing antibodies and methods for their uses.

HIV-1 neutralizing antibodies and uses thereof

Methods of inhibiting complement factor H (CFH) comprising administering an antibody that binds CFH

In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelope selections from individual CH505, and methods for swarm immunizations using combinations of HIV-1 envelopes.

Compositions comprising HIV envelopes to induce CH235 lineage antibodies

Anti-complement factor H antibodies

The invention provides compositions and methods to induce and boost antibody response, including but not limited to IgG responses binding to HIV-1 in a subject in need thereof, wherein the induced/boosted plasma level of the antibody responses, for example V3 and/or CD4 binding site antibody responses, is over a threshold level and is associated with reduced risk of maternal-to-child-transmission (MTCT) of HIV-1.

Methods for reducing HIV-1 mother-to-child transmission by inducing V3-specific or CD4 binding site-specific antibodies

The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.

Consensus/ancestral immunogens

Disclosed herein are Complement factor H (CFH) antibodies and methods of using the antibodies.

Complement factor H antibodies

The present invention relates, in general, to HIV-1 and, in particular, to broadly neutralizing HIV-1 antibodies, and to HIV-1 immunogens and to methods of using such immunogens to induce the production of broadly neutralizing HIV-1 antibodies in a subject (e.g., a human).

Antibody evolution immunogens

The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method.

Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies

The present invention relates, in general, to an immunogen for HIV vaccination and, in particular, to a method of inducing the production of protective anti-HIV antibodies by targeting B cell germline and clone intermediates using a combination of HIV envelope and non-HIV immunogens. The invention also relates to compositions suitable for use in such a method.

Method of inducing the production of protective anti-HIV-1 antibodies

The invention relates to the identification of monoclonal HIV-1 neutralizing antibodies, such as, but not limited to, antibodies that bind to the CD4 binding site (CD4bs) of HIV-1 gp120, their recombinant expression and purification and uses. In certain aspects, the invention provides a pharmaceutical composition comprising anyone of the antibodies of the invention or fragments thereof or any combination thereof. In certain aspects the invention provides methods to treat or prevent HIV-1 infection in a subject comprising administering to the subject a pharmaceutical composition comprising any one of the inventive antibodies or fragments thereof.

HIV-1 neutralizing antibodies and uses thereof (CD4bs antibodies)

The invention is directed to HIV-1 neutralizing antibodies, CD4 binding site and V3 glycan antibodies, and methods for their uses.

HIV-1 neutralizing antibodies and uses thereof (V3 antibodies)

Growing community of inventors

Durham, NC, United States of America

Hua-Xin Liao